ProteinQure’s Post

🚀 Big News from ProteinQure! 🚀 Exciting update: ProteinQure, has validated our lead program for triple-negative breast cancer (TNBC) and I'm thrilled to announce that our findings will be presented at the upcoming AACR conference in San Diego, showcasing our commitment to advancing cancer research (see press release for poster details). Our novel Peptide Drug Conjugate (PDC) has shown exceptional efficacy in battling TNBC, even in treatment-resistant cases. Performed at Dr. David Cescon's lab at Princess Margaret Cancer Centre/University Health Network, our PDC demonstrated remarkable results in over 15 heterogeneous Patient-Derived Xenograft (PDX) models. As a computational drug discovery company, it has been amazing to stop trying to convince people with benchmarks on irrelevant data sets and start pointing to multiple drug candidates that ProteinQure has enabled. We are looking forward to collaborating further with world-class clinicians on our Phase I clinical trial in the near future. I will be at AACR to learn from and speak to researchers about our development candidate and planned FIH trial. #ProteinQure #CancerResearch #AACR2024 #PrecisionMedicine #DrugDevelopment #AIDrugDiscovery https://lnkd.in/geZTFMtY

Chromosome translocations have been associated with human malignancy (mainly blood leukemia like CML and Philadelphia chromosomes) for a long time. Soft tissue human sarcomas have also been characterized by such chromosome abnormalities or fusions. See- Targeting fusion oncoproteins in childhood cancers: challenges and future opportunities for developing therapeutics Sharad K Verma, PhD, Keren L Witkin, PhD, Anu Sharman, PhD, Malcolm A Smith, MD, PhD-JNCI: Journal of the National Cancer Institute, Volume 116, Issue 7, July 2024, Pages 1012–1018, https://lnkd.in/daRxd6mg Fusion oncoproteins are associated with childhood cancers and have proven challenging to target, aside from those that include kinases. As part of its efforts for targeting childhood cancers, the National Cancer Institute recently conducted a series on Novel Chemical Approaches for Targeting Fusion Oncoproteins. Key learnings on leading platforms and technologies that can be used to advance the development of molecular therapeutics that target fusion oncoproteins in childhood cancers are described. Recent breakthroughs in medicinal chemistry and chemical biology provide new ground and creative strategies to exploit for the development of targeted agents for improving outcomes against these recalcitrant cancers? Recurrent chromosomal translocations that produce fusion oncoproteins are a hallmark of selected cancers, particularly among those associated with childhood, and many are pathognomonic of specific cancer types. These translocations generate fusions of normal genes that encode novel proteins that acquire oncogenic function, often by dysregulating protein complexes that control gene expression or chromatin state, thus altering developmental programs that lead to transformation of the unique cell of origin for each cancer. Over the past 2 decades, there have been some clear success stories in improving outcomes in pediatric and adolescent and young adult cancers. For example, mortality in the United States for acute lymphoblastic leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma declined by approximately 40%, 60%, and 80%, respectively, between 2000 and 2022. These successes at least partially result from the availability of new therapeutic agents for these cancers. However, new active agents are lacking for other childhood-associated cancers, such as soft tissue sarcomas like rhabdomyosarcoma (frequently driven by the PAX3/7::FOXO1 gene fusion), bone cancers like Ewing sarcoma (frequently driven by the EWSR1::FLI1 gene fusion) and osteosarcoma, and many types of childhood brain tumors. In these cancers that lack new therapeutic approaches, similar declines in mortality have not been observed and patients continue to be treated with toxic chemotherapy and radiation, leading to substantial acute and long-term morbidity. Improving outcomes for recalcitrant cancers like these requires the development of new active drugs

Immunovia's Norma Alonzo Palma PhD presented data from model development study at 2024 AACR Pancreatic Cancer Conference, hosted by the American Association for Cancer Research.   During the conference, Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. “We are grateful to have been selected by the AACR reviewers to present the model-development-study results at this inspiring conference of pancreatic cancer advances. Rigorous scientific review and dissemination of our data will be critical for driving adoption of our next-generation test following its launch next year,” said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia.    Read more about the presentation at the conference on the link below. #PancreaticCancer #EarlyDetection #AACR

The "International Symposium on Cell Engagers and Cancer Immunotherapy," hosted by Elpiscience Biopharmaceuticals, has wrapped up with great success. If you missed it, don't worry! We'll continue to bring you the exciting highlights and breakthrough insights shared at the event. Dr. Philip.D. Greenberg from the University of Washington delivered one of the standout presentations, titled "Engineering T Cells to Eradicate Solid Tumors." Dr. Greenberg‘s research spans the spectrum from basic research to clinical applications, particularly focusing on engineering CD8 T cells to develop innovative treatment strategies for pancreatic cancer. His team has advanced to the phase 1/2 clinical stage with an autologous transgenic TCR-TMSLN therapy for patients with metastatic pancreatic cancer. Notably, their Mechanism of Action (MOA) study revealed the pivotal role of the TGF-beta signaling pathway in T cell anti-tumor activity. To further elevate the efficacy of cell therapy, Dr. Greenberg's team is exploring various approaches to enhance T cell survival and function. These include FAS-41BB engineered T cells by a Synthetic Immunomodulatory Fusion Proteins (IFPs) strategy, engineering a composite and interactive CD4 and CD8 T cell response to the tumor, specific TCRs targeting KRAS, and the exhausted T cell differentiation by E3 ligases. Stay tuned for more exciting updates and deep dives into the revolutionary advancements shared at the symposium！ 🚀🔬 #ImmuneOncology #CancerResearch #SymposiumHighlights #CellEngagers #BiME

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer treatment, offering targeted delivery of potent drugs to cancer cells while minimizing damage to healthy tissues. However, challenges remain in optimizing their efficacy and tolerability. At Zymeworks, our researchers are developing next-generation #ADCs designed to achieve robust anti-tumor activity. Advances in technology and understanding of ADCs offer opportunities to improve their efficacy and tolerability, both as monotherapy and in combination with other cancer treatments. The coordinated design and optimization of ADCs holds promise for providing clinical benefits to cancer patients, and the potential for a positive outcome. Learn more in this article from BioSpace authored by our Chief Scientific Officer Paul Moore, PhD: https://lnkd.in/e44Y5y9s #AACR24

Great article from Biospace on hot topics from this weeks #AACR 2024 in San Diego. Synthekine Optimistic About Early Safety Signals for IL-2 Treatment. Finnish Biotech ‘TILTs’ at Success in Ovarian Cancer TILT Biotherapeutics Ltd Merck Kelun Biotech Present Promising Data from ADC in Gastric Cancer. ALX Oncology and Investigators ‘Encouraged’ by Phase I/II R/R B-NHL Data. So Far So Good for Obsidian Therapeutics TIL Therapy in Metastatic Melanoma. AstraZeneca ATM Inhibitor Shows Promise in Glioblastoma. Transgene and NEC Report Positive Phase I Data in Head and Neck Cancer. Diakonos Oncology Dendritic Cell Vaccine Shows Promise in Glioblastoma. Vincerx Pharma Debuts Data From Lead ADC for Solid Tumors. Poseida Therapeutics, Inc. CAR-T Therapy Shows 60% Response Rate in Multiple Myeloma. Read more in the article now. Encouraging to see so many advances in cancer research. Russ@bridge1.net #cancerresearch #oncology #canceradvances #solidtumor #multiplemyeloma #ovariancancer #AACR24 #AACR2024 https://lnkd.in/g4ji2RzQ

⚕️ Research Luxembourg: Taking the fight to #cancer 👏 A Luxembourg Institute of Health (LIH) in collaboration with Sprint Bioscience and the Karolinska Institutet has unlocked the potential of STING agonist-based cancer #immunotherapy. 🔬 The promising new strategy for cancer treatment stems from an immunotherapy combination that pairs a STING agonist, which enhances the #immunesystem, with a compound that targets #autophagy, a mechanism implicated in cancer immune evasion. This dual therapeutic approach markedly reduced tumour size and improved #survivalrates in preclinical studies, offering new hope of shifting the paradigm in #cancertreatment. 🗣 Dr. Bassam Janji (PhD, HDR), Head of the TIME group at LIH, adds: "This research offers a new hope for overcoming the several disappointments encountered in past clinical trials with STING agonists. By enhancing the STING pathway and circumventing cancer’s immune evasion strategies, we have the potential to develop durable and powerful new immunotherapies." 🔗 Learn more about this #research: https://lnkd.in/dHKiP923 #cancerresearch #cancerimmunotherapy #medicalbreakthrough

First Ascent Biomedical shares data for new AI cancer screening platform Jim Foote, CEO and co-founder of First Ascent Biomedical told Clinical Trials Arena: “The most striking finding was the clinical outcomes when the FPM data was used to guide treatment. In our study, 83% of patients guided by FPM data received clear clinical benefit: their cancer either shrinking or becoming undetectable (partial or complete response), and 83% also performed better on their study treatment compared to their prior treatment, which is a routinely used measure of success in precision cancer medicine studies. While both these findings are what we expected, it is exciting to see such a promising signal from our first clinical study.” - https://lnkd.in/dPZz-rxt #clinicaltrials #aiinhealthcare #cancerscreening

Recently published research describes the development of a blood test capable of identifying early-stage cancers in human organs. The test analyzes DNA methylation patterns, providing a non-invasive and accurate method for detecting cancer at its early stages. This breakthrough holds significant potential for improving cancer diagnosis and prognosis, paving the way for more effective and timely interventions in the battle against cancer. The research marks a crucial advancement in the ongoing efforts to enhance cancer screening methodologies. 🩸🔍 #BloodTest #CancerDetection #EarlyCancerDiagnosis #MedicalResearch #InnovativeHealthcare 🌐🏥

Researchers Discover a New Way to Enhance HER2+ Breast Cancer Treatments New research findings promise significant advances in the treatment of HER2+ breast cancer. The research team successfully inhibited the DUSP6 protein using experimental drug molecules, significantly enhancing the therapeutic effect of existing HER2 inhibitors. In animal studies, the use of the drug proved to be safe and effective, highlighting the potential of DUSP6 in future cancer drug research. Although these molecules are not yet suitable for patient use, the research results provide important evidence of DUSP6's promise in the development of cancer treatments. The study "DUSP6 inhibition overcomes Neuregulin/HER3-driven therapy resistance in HER2+ breast cancer" has been published in the prestigious journal EMBO Molecular Medicine. This breakthrough would not have been possible without the support of Finnish foundations, particularly the Cancer Foundation Finland, the Foundation for the Finnish Cancer Institute, and the Finnish Cultural Foundation. Read the full article https://lnkd.in/d-gyX5yA. #CancerResearch #HER2BreastCancer #DUSP6 #MedicalScience #Research